Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Oct 3;80(10):2782-2789.
doi: 10.1093/jac/dkaf297.

Population pharmacokinetics of bictegravir in real-world people with HIV

Collaborators, Affiliations

Population pharmacokinetics of bictegravir in real-world people with HIV

Pierre Ekobena et al. J Antimicrob Chemother. .

Abstract

Objectives: Bictegravir is an integrase strand transfer inhibitor widely prescribed due to its good efficacy and safety profile. Its pharmacokinetic (PK) profile has not been described in real-world settings yet. This study aimed to characterize bictegravir population PK in people with HIV (PWH) and to identify covariates affecting its disposition.

Methods: Bictegravir concentrations were obtained from PWH as part of a therapeutic drug monitoring (TDM) follow-up performed at the Lausanne University Hospital, Switzerland, between July 2019 and July 2024. Demographic data, clinical data and co-medications were recorded during the routine Swiss HIV Cohort Study (SHCS) visits. A population PK model was developed using a non-linear mixed-effect approach with Monolix®.

Results: A total of 708 steady-state plasma concentrations from 572 PWH were available for the analysis. A one-compartment model with first-order absorption and elimination best characterized bictegravir PK. Age and body weight were found to significantly affect bictegravir clearance, individuals of 51 years weighing 100 kg showing a 13% increase, and those aged 80 years weighing 70 kg a 11% decrease, relative to an individual weighing 70 kg and aged 51 years. These effects are not deemed clinically significant and do not warrant a clinical intervention.

Conclusions: Considering the good safety and efficacy profile of bictegravir, routine TDM is of limited value for bictegravir. However, TDM of bictegravir could be beneficial in case of suspected viral resistance or non-adherence, in special subpopulations (i.e. obese individuals and pregnant women), or to monitor drug-drug interactions.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Simulated bictegravir steady-state concentrations under the standard 50 mg once-daily regimen. The dotted line shows the minimum concentration recommended for efficacy (760 ng/mL). (a) Simulated percentiles for the typical patient (i.e. 51 years old and BW of 70 kg). The solid light line represents the median (50% percentile), while the dark shaded areas are the prediction intervals, with the light shaded areas corresponding to the 90% prediction intervals. (b) Simulated median concentrations for the different groups of individuals.

References

    1. European Medicines Agency . Biktarvy epar public assessment report 2018. https://www.ema.europa.eu/en/documents/assessment-report/biktarvy-epar-p....
    1. Gilead Sciences . Biktarvy. U.S. Food and Drug administration. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210251Orig1s000M....
    1. Panel on Antiretroviral Guidelines for Adults and Adolescents . Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV. Department of Health and Human Services. https://clinicalinfo.hiv.gov/sites/default/files/guidelines/documents/ad....
    1. European AIDS Clinical Society . European AIDS Clinical Society Guidelines Version 10.0. https://www.eacsociety.org/media/2019_guidelines-10.0_final.pdf.
    1. Gallant JE, Thompson M, DeJesus E et al. Antiviral activity, safety, and pharmacokinetics of bictegravir as 10-day monotherapy in HIV-1-infected adults. J Acquir Immune Defic Syndr 2017; 75: 61–6. 10.1097/QAI.0000000000001306 - DOI - PMC - PubMed

MeSH terms